Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy.
BACKGROUND Both bone marrow-derived mesenchymal stem cells (MSCs) and c-kit(+) cardiac stem cells (CSCs) improve left ventricular remodeling in porcine models and clinical trials. Using xenogeneic (human) cells in immunosuppressed animals with acute ischemic heart disease, we previously showed that these 2 cell types act synergistically. OBJECTIVES To more accurately model clinical applicatio...
متن کاملThe Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy
Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34(+) and CD 133(+) stem cells have been applied...
متن کاملStem Cell Therapy in Hypoxic Ischemic Encephalopathy
Introduction there are one million deaths from asphyxia in newborn annually. Management of this newborn is only supportive. Autologuse stem cell therapy may reduce mortality and long term morbidity. Outcome of asphyxiated newborn is related to damage CNS cells. Stem cells prevent Apoptosis and induce repairmen of injured neurons. Methods in a review study all article related to three keyword...
متن کاملEffects of puerarin combined with conventional therapy on ischemic stroke
This study evaluated the use of conventional therapy combined with puerarin on ischemic stroke. Eighty patients with ischemic stroke admitted to Tangshan Gongren Hospital from March 2014 to September 2015 were randomly divided into two groups. The control group was treated with conventional therapy. The observation group was treated with an additional puerarin injection of 400 mg/day. The patie...
متن کاملCell Therapy for Nonischemic Cardiomyopathy
Currently, nonischemic dilated cardiomyopathy (NICM) represents the leading cause of advanced heart failure, accounting for >50% of all heart transplantation procedures. We propose that when compared with patients with ischemic heart failure (IHF), patients with NICM demonstrate a more favorable clinical response to cell therapy, which offers a potential novel promising treatment approach for t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2015
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2015.08.879